Welcome to our dedicated page for Staar Surg SEC filings (Ticker: STAA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The STAAR Surgical Company (NASDAQ: STAA) SEC filings page on Stock Titan brings together the company’s official disclosures from the U.S. Securities and Exchange Commission. STAAR is a medical device manufacturer focused on ophthalmic surgery, and its filings provide detailed information on its implantable intraocular lens business, corporate actions, and governance.
Investors can review Current Reports on Form 8-K in which STAAR reports material events, such as the August 2025 Agreement and Plan of Merger with Alcon, subsequent amendments, the go-shop process, adjournments of special meetings of stockholders, and later communications about the failure to obtain shareholder approval and the intended termination of the merger agreement. Other 8-K filings describe litigation related to the merger proxy statement, preliminary and final financial results, and leadership changes, including the appointment of a Chief Financial Officer and the creation of a Capital Stewardship Committee of the Board.
Filings also confirm that STAAR’s common stock is listed on Nasdaq under the symbol STAA and document how the proposed merger, if completed, would have affected listing status and registration. By reading these documents, users can trace the evolution of STAAR’s strategic transaction with Alcon, the role of major shareholders in the process, and the company’s decision to remain a standalone, publicly traded entity after the merger was not approved.
On Stock Titan, STAAR’s SEC filings are updated as new documents are released on EDGAR. AI-powered tools summarize lengthy filings such as 8-Ks and related exhibits, helping users quickly identify key terms, conditions, and outcomes without reading every page. This makes it easier to track transaction terms, board and management changes, and other disclosures that shape the outlook for STAA within the ophthalmic medical device industry.
Broadwood Partners and its affiliates filed additional proxy materials for STAAR Surgical’s contested sale to Alcon. The group updated its LetSTAARShine.com website to include a November 18, 2025 Investing.com article describing new board-level dissent over STAAR’s amended $28-per-share merger agreement with Alcon. The article notes that one director opposed the revised terms, while five directors approved them after efforts to obtain a higher price did not succeed and a tail fee provision was removed.
These materials relate to a special stockholder meeting currently scheduled for October 23, 2025 to consider the transaction, as well as a separate special meeting Broadwood intends to call to remove certain directors. The exhibits and website highlight prior public opposition to the deal, recommendations by multiple proxy advisors to vote against it, and Broadwood’s campaign criticizing the proposed sale and supporting board changes.
STAAR Surgical (STAA) reported an insider equity change on Form 4. On 11/12/2025, Director Wei Jiang acquired 20,967 shares of common stock at $0 per share, following the vesting and settlement of restricted stock units (Transaction Code: M).
After this transaction, Jiang beneficially owns 45,477 shares, held directly. The RSUs were granted on May 12, 2025 and vest in three equal tranches of 20,967 shares each: on August 12, 2025, November 12, 2025, and January 12, 2026.
According to prior disclosures, Jiang is serving through fiscal 2025 as a special strategic advisor to the company’s Asia Pacific business in the temporary role of Chief of APAC Strategy; this transaction reflects vesting tied to that service.
STAAR Surgical Company entered into Amendment No. 1 to its merger agreement with Alcon Research, LLC and Rascasse Merger Sub, Inc., adding a go-shop window and adjusting termination terms.
The amendment permits the Company to solicit, facilitate and encourage Acquisition Proposals, including by sharing non-public information, from
Separately, the special meeting to vote on the merger has been postponed to
STAAR Surgical (STAA): Activist DFAN14A update and governance push. Broadwood and affiliates updated their campaign website and filed materials that incorporate a letter from Yunqi Capital, a 5.1% shareholder. Yunqi cites STAAR’s third-quarter metrics to argue against the proposed $28-per-share sale to Alcon.
According to Yunqi’s letter, reported operating expenses were $59.4 million; excluding $5.9 million of merger-related costs, the underlying run rate was $53.5 million, which it says annualizes to $214 million versus prior guidance of $225 million. Yunqi also notes cash, cash equivalents, and investments of $192.7 million, up from $189.9 million at the prior quarter-end. The dissident group urges shareholders to use the GREEN proxy card for the special meeting scheduled for October 23, 2025, and contends that recent performance supports terminating the Alcon transaction.
Yunqi Capital filed a Notice of Exempt Solicitation concerning STAAR Surgical (STAA) and the proposed sale to Alcon. In an attached letter, the 5.1% shareholder urges the Board to terminate the $28 per share transaction, citing what it describes as strong third‑quarter performance and improving fundamentals.
Yunqi points to reported operating expenses of $59.4 million, including $5.9 million of merger‑related costs, implying an underlying run rate of $53.5 million that it says annualizes to $214 million versus prior guidance of $225 million. It also notes cash, cash equivalents, and investments of $192.7 million, up from $189.9 million. The firm challenges Alcon’s presentation of China market data, asks STAAR’s Board to communicate directly with shareholders, and proposes adding a director with meaningful ownership. Yunqi states that 72% of outstanding shares had voted against the deal as of the originally scheduled October 23 special meeting.
STAAR Surgical Company (STAA) filed its Q3 report and detailed a pending merger with Alcon. Under the agreement, each share will be converted into $28.00 in cash at closing, subject to stockholder approval and other conditions. The HSR waiting period has expired, and the special meeting to vote on the merger is scheduled for December 3, 2025.
Q3 results: Net sales were $94.7 million versus $88.6 million a year ago, with gross margin at 82.2%. Net income was $8.9 million. Year‑to‑date net sales were $181.6 million versus $265.0 million, and the company reported a net loss of $62.1 million, reflecting $27.9 million in restructuring, impairment and related charges and $5.9 million in merger-related costs.
China dynamics remain central. Q3 China sales were $55.8 million, including $25.9 million recognized from a December 2024 shipment collected in Q3 at 100% gross margin. The company shifted to consignment arrangements in China and increased consigned inventory to manage tariff risk. Cash and equivalents were $176.2 million, with year‑to‑date operating cash flow of $(30.3) million. The board authorized a $30 million buyback; $23.5 million remained available as of quarter end.
STAAR Surgical Company furnished a press release reporting its financial results for the quarter ended September 26, 2025. The release is provided as Exhibit 99.1 to this report.
The information furnished under Item 2.02 is expressly stated as not being “filed” for purposes of Section 18 of the Exchange Act and will not be incorporated by reference into Securities Act or Exchange Act filings.
Alcon filed investor materials supporting its proposed all-cash acquisition of STAAR Surgical at $28 per share, and plans outreach to STAAR stockholders. The materials emphasize offer context and comparisons, noting a 59% premium to the 90‑day VWAP of $18 and a 47% premium to the median sell-side price target of $19. Alcon also states it is the only interested buyer and encourages a board‑run 45‑day go‑shop without matching rights or a break‑up fee if a superior proposal emerges.
The communications reiterate that STAAR’s definitive proxy statement on Schedule 14A was filed and mailed on September 16, 2025, and include standard forward‑looking statements and risk factors, such as the need for stockholder approval and regulatory clearances. Alcon positions the transaction as aligned with sector precedents and at the high end of comparable ophthalmology deal multiples.
FAQ
What is the current stock price of Staar Surg (STAA)?
What is the market cap of Staar Surg (STAA)?
